Cash outflow for purchase of trading, available-for-sale securities and held-to-maturity securities.

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=82896770&loc=d3e26853-111562

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (a),(b)
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3213-108585

Name:	us-gaap_PaymentsToAcquireMarketableSecurities
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

Collaboration Agreements (Intella Therapeutics) (Details) - USD ($) $ in Thousands	1 Months Ended	6 Months Ended
	Apr. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Payments to Acquire Marketable Securities		$ 477,408	$ 228,942
Collaborative Arrangement [Member] \| Intellia Therapeutics [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Other Research and Development Expense	$ 75,000
Payments to Acquire Marketable Securities			$ 50,000